YOLFTbeta
60

Beijing Wantai Biological Pharmacy Enterprise Co Ltd

603392 · SHG · Healthcare / Biotechnology

22.85CNY-0.66 (-2.81%)

Price History

Full chart

Market Stats

Previous Close23.51
Open23.42
Day Range22.83 – 23.48
52-Week Range24.70 – 58.66
Volume4.69M
Market Cap34.57B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.30
Dividend Yield0.00%
Beta0.74
50-Day Avg28.57
200-Day Avg35.95

About

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer screening; and TB-IGRA for large population screening. It also provides diagnostic assays, such as high-value Hepatitis B core antibody tests, Hepatitis E Urine tests, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays; and enzyme-linked immunosorbent assay (ELISA), colloidal gold, molecular, clinical laboratory quality control products, and bioactive materials for various infectious diseases, such as HIV, Hepatitis, Tuberculosis, and Influenza A/B. In addition, the company offers core diagnostic solutions comprising chronic disease management, integrated Hepatitis E screening and prevention, full lifecycle women's health programs, and intelligent laboratory services. Further, it provides medical instruments, diagnostic tests, quality control products, bioactive materials, and diagnostics solutions; and HPV, Hepatitis E, and Nasal Spray COVID-19 vaccines. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a subsidiary of Yangshengtang Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Zhiming Jiang
  • Employees4.12K
  • HeadquartersNo. 31, Kexue Yuan Road, Beijing, China, 102206, China
  • Websitehttps://www.ystwt.com

Leadership

  • Ms. Zhiming JiangGM & Director · b. 1973
  • Mr. Yun LuCFO & Director · b. 1989
  • Mr. Pan HuirongDeputy General Manager · b. 1978
  • Gangsheng LiAccounting Supervisor

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue499.06M596.23M680.71M844.08M949.52M982.69M1.18B2.35B5.75B11.19B5.51B2.25B1.82B
Growth (%)-+19.47%+14.17%+24.00%+12.49%+3.49%+20.46%+98.88%+144.25%+94.51%-50.73%-59.25%-18.99%
Cost of Revenue122.26M147.23M178.82M235.18M294.29M283.71M350.41M473.60M850.67M1.20B1.08B866.34M921.83M
Gross Profit376.80M449.00M501.90M608.91M655.24M698.98M833.34M1.88B4.90B9.99B4.43B1.38B897.14M
Gross Margin75.50%75.31%73.73%72.14%69.01%71.13%70.40%79.88%85.21%89.29%80.34%61.42%49.32%
Operating Expense280.57M333.77M380.06M477.47M476.49M409.86M615.01M1.11B2.57B4.39B3.03B1.29B1.32B
Operating Income96.23M115.24M121.84M131.44M178.74M289.12M218.33M775.20M2.33B5.60B1.40B93.84M-426.41M
Operating Margin19.28%19.33%17.90%15.57%18.82%29.42%18.44%32.93%40.49%50.03%25.43%4.18%-23.44%
EBITDA104.65M130.55M131.06M152.26M156.66M185.73M229.86M809.21M2.33B5.40B1.58B-65.06M-128.70M
EBITDA Margin20.97%21.90%19.25%18.04%16.50%18.90%19.42%34.37%40.59%48.28%28.66%-2.90%-7.08%
Net Income79.83M118.46M119.36M148.19M150.41M293.07M208.86M677.00M2.02B4.74B1.25B106.24M-398.27M
Net Income Margin16.00%19.87%17.53%17.56%15.84%29.82%17.64%28.76%35.15%42.34%22.64%4.73%-21.90%
R&D76.01M97.37M109.47M130.10M158.82M138.34M165.98M314.33M681.82M1.10B1.20B886.05M560.80M
R&D as % of Total Revenue15.23%16.33%16.08%15.41%16.73%14.08%14.02%13.35%11.86%9.83%21.74%39.46%30.83%
Interest Expense--1.17M05.17M6.32M1.38M2.06M6.22M8.43M8.01M8.32M6.46M
Interest Expense % of Total Revenue--0.17%0.00%0.54%0.64%0.12%0.09%0.11%0.08%0.15%0.37%0.36%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets606.98M805.50M1.10B1.45B1.66B1.81B2.16B3.50B7.05B16.23B15.71B14.69B14.04B
Total Liabilities224.92M225.19M378.93M494.76M756.80M444.24M584.19M923.29M2.48B3.66B2.83B2.24B2.01B
Total Equity382.06M580.32M689.94M889.05M878.33M1.35B1.56B2.55B4.47B12.34B12.70B12.26B11.86B
Cash133.28M272.88M320.73M308.04M340.04M427.04M283.60M710.67M1.42B5.19B3.82B2.39B2.43B
Total Debt30.24M31.00M120.56K-218.35M21.00M21.00M77.66M287.06M277.86M208.86M278.79M-
Net Debt-103.04M-241.88M-320.61M-308.04M-121.70M-406.04M-262.60M-633.01M-1.13B-4.91B-3.42B-2.11B-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow97.83M132.43M151.84M129.40M146.97M208.31M272.68M468.21M1.68B4.13B1.60B355.08M89.75M
Investing Cash Flow-106.28M-71.54M-225.28M-197.74M-301.71M-352.52M-198.37M-295.40M-1.01B-3.51B-2.12B-1.50B-
Financing Cash Flow12.43M78.40M-30.89M105.82M209.39M-29.05M-5.18M379.79M52.79M3.13B-893.26M-612.74M-
Capital Expenditure82.12M77.43M77.92M131.26M214.65M246.06M162.00M390.44M1.05B929.91M1.16B887.35M805.16M
Free Cash Flow15.71M55.00M73.92M-1.86M-67.69M-37.75M110.68M77.77M634.16M3.20B378.15M-532.27M-715.41M
Dividends Paid17.27M2.09M105.34M-4.56M6.29M1.04M1.65M108.40M121.41M904.49M410.18M2.28M
FCF to OCF16.06%41.53%48.68%-1.44%-46.05%-18.12%40.59%16.61%37.70%77.50%23.57%-149.90%-797.08%
Dividend Paid to FCF109.91%3.80%142.51%--6.73%-16.67%0.94%2.13%17.09%3.79%239.19%-77.06%-0.32%

Earnings

Report DateMay 29, 2020Aug 21, 2020Oct 27, 2020Mar 4, 2021Apr 21, 2021Aug 17, 2021Oct 27, 2021Feb 14, 2022Apr 15, 2022Aug 25, 2022Oct 17, 2022Jan 19, 2023Apr 20, 2023Aug 24, 2023Oct 27, 2023Mar 28, 2024Jun 30, 2024Oct 24, 2024Apr 11, 2025
EPS Estimate0.00------------1.081.170.980.170.110.13
EPS Actual0.540.290.260.350.480.490.530.941.511.551.380.881.380.350.09-0.440.110.01-0.13
Surprise--------------67.59%-92.31%-144.90%-35.29%-90.91%-200.00%
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-market

Key Statistics & Ratios

Market Cap34.57B
Enterprise Value30.43B
Trailing P/E0.00
Forward P/E0.00
Price / Sales17.08
Price / Book2.90
EPS-0.30
Book Value9.28
Revenue (TTM)2.02B
Gross Profit (TTM)848.61M
EBITDA-394.50M
Profit Margin-18.90%
Operating Margin-23.03%
Return on Equity-3.31%
Return on Assets-3.11%
Shares Outstanding1.26B
Shares Float261.21M
Beta0.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
1.00Jun 5, 2023
20221×
0.14Apr 21, 2022
20211×
0.12May 18, 2021

Stock Splits

  • Jun 5, 20237:5
  • Apr 21, 202229:20
  • May 18, 20217:5